QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of anagrelide and abarelix. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for anagrelide, when combined with abarelix (100%). We do not expect any change in exposure for abarelix, when combined with anagrelide (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
Anagrelide has a mean oral bioavailability [ F ] of 70%, which is why the maximum plasma levels [Cmax] tend to change with an interaction. The terminal half-life [ t12 ] is rather short at 1.3 hours and constant plasma levels [ Css ] are reached quickly. Protein binding [ Pb ] is not known and the volume of distribution [ Vd ] is very large at 840 liters. The metabolism mainly takes place via CYP1A2.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither anagrelide nor abarelix increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither anagrelide nor abarelix increase anticholinergic activity.
QT time prolongation
Rating: In combination, anagrelide and abarelix can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||ana||aba|
|Peripheral edema||21.0 %||21.0||n.a.|
|Abdominal pain||16.0 %||16.0||n.a.|
Vomiting (10%): anagrelide
Loss of appetite (8%): anagrelide
Dyspepsis (5%): anagrelide
Fever (9%): anagrelide
Malaise (6%): anagrelide
Chest pain (8%): anagrelide
Tachycardia (8%): anagrelide
Ventricular tachycardia: anagrelide
Rash (8%): anagrelide
Pruritus (6%): anagrelide
Backache (6%): anagrelide
Cough (6%): anagrelide
Interstitial lung disease: anagrelide
Hemorrhage (3%): anagrelide
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.